Pharma Industry
Industry: Email Alert RSS FeedA multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution
Journal of Drugs in Dermatology, Jan-Feb, 2005 by Michael H. Gold, Jaggi Rao, Mitchel P. Goldman, Tancy M. Bridges, Virginia L. Bradshaw, Molly M. Boring, April N. Guider
Thirteen of the patients evaluated were randomized to receive twice daily application of topical 1% clindamycin antibiotic solution; 12 of the patients were randomized to receive twice weekly blue light therapy. The number of non-inflammatory acne vulgaris lesions was evaluated at each visit and the number of inflammatory acne vulgaris lesions was evaluated at each study visit as well.
Topical 1% Clindamycin Solution
- Most Popular Articles in Health
- Fuel your workout: exercisers who eat before they work out have more energy ...
- Soothe a dry, itchy scalp: 5 easy expert solutions
- Cocktails and calories: Beer, wine and liquor calories can really add up. ...
- The sour truth about apple cider vinegar - evaluation of therapeutic use
- The, six best supplements you've never heard of: these secret weapons can ...
- More »
The number of non-inflammatory acne vulgaris lesions at the first treatment visit varied from 9 to 95 lesions, with an average of 29 non-inflammatory lesions. At the 4-week treatment evaluation, lesion counts for non-inflammatory acne vulgaris lesions varied from 7 to 78, with an average of 20.3 lesions. The percent average improvement was calculated to be 30%. For the 9 patients in this group of patients who completed the 4-week follow-up phase, lesion counts for non-inflammatory acne vulgaris lesions varied from 4 to 38 lesions, with an average of 12.5 lesions. This sub-group of patients averaged a lesion count of 10.8 lesions at the end of the 4-week treatment phase (compared to the 20.3 lesions seen in this group as a whole). This shows a 14% change in the follow-up period for this sub-group of patients.
For inflammatory acne vulgaris lesions in the topical 1% clindamycin solution group of patients, the number of inflammatory acne vulgaris lesions present at the first treatment varied from 12 to 32 lesions, with an average of 17.4 lesions. At the 4-week treatment evaluation, lesion counts for inflammatory acne vulgaris lesions varied from 4 to 43 lesions, with an average of 15 lesions. The percent average improvement in this group was 14%. For the 9 patients in this group of patients who completed the 4-week follow-up phase, lesion counts for inflammatory acne vulgaris lesions varied from 4 to 19 lesions, with an average of 10.4 lesions. This sub-group of patients averaged a lesion count of 10.8 lesions at the end of the 4-week treatment phase (compared to 15 lesions seen in this group as a whole). The percentage change in this sub-group of individuals was not significant.
[FIGURE 2 OMITTED]
Blue Light Group
Twelve patients completed the 4-week treatment phase and 9 of the patients finished their 4-week follow-up phase evaluations. Non-inflammatory acne vulgaris lesions present at the first treatment evaluation varied from 9 to 120 lesions, with an average of 29.4 non-inflammatory acne vulgaris lesions. At the 4-week treatment evaluation, lesion counts for non-inflammatory acne vulgaris lesions varied from 5 to 54 lesions, with an average of 23.3 lesions. The percent improvement was 21%. For the nine patients in this group who completed the 4-week follow-up phase, non-inflammatory acne vulgaris lesion counts varied from 8 to 40 lesions, with an average of 21.4 lesions. This subgroup of patients averaged a lesion count of 21.6 at the end of the 4-week treatment phase (as compared to 23.3 lesions seen in this group as a whole). The percentage change in this sub-group of individuals was not significant.